Prediction of Version Outcomes for External Maneuvers of Breech Fetus by Assessment of Breech Progression Angle
Launched by IRCCS AZIENDA OSPEDALIERO-UNIVERSITARIA DI BOLOGNA · Feb 4, 2025
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a procedure called cephalic version, which is used to turn a baby that is in a breech position (feet or bottom first) into a head-down position before delivery. Breech presentations occur in about 3-4% of pregnancies at term and can increase the risks associated with delivery. The goal of the study is to explore if using a specific type of ultrasound can help predict whether this turning maneuver will be successful. By using this ultrasound, researchers hope to measure a specific angle that reflects how well the baby is positioned to descend during labor.
To participate in this trial, women must be over 18 years old and have a single pregnancy at term (between 37 and 42 weeks) with their baby in a breech position. However, certain conditions, like low amniotic fluid or previous uterine surgeries, may exclude someone from participating. Women who join the study can expect to undergo the ultrasound assessment as part of the evaluation process, helping to determine the best approach for their delivery. This research could provide valuable insights for improving outcomes for babies in breech presentations.
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Women \>18 years of age with a single pregnancy at term (37-42 gestational weeks) with a fetus in breech presentation
- • Acquisition of Informed Consent Form
- Exclusion Criteria:
- • Oligohydramnios: maximum flap \< 2cm
- • Placenta previa
- • Uterine malformations
- • Regular uterine dynamics
- • Metrorrhagia
- • Contraindications to vaginal delivery
- • Premature rupture of membranes
- • Nonreassuring cardiotocographic tracing
- • Previous uterine surgery
About Irccs Azienda Ospedaliero Universitaria Di Bologna
IRCCS Azienda Ospedaliero-Universitaria di Bologna is a prestigious research and healthcare institution in Italy, renowned for its commitment to advancing medical science and patient care through innovative clinical research. As an IRCCS (Istituto di Ricovero e Cura a Carattere Scientifico), it integrates clinical practice with scientific research, facilitating the translation of laboratory findings into effective treatment strategies. The institution fosters a multidisciplinary approach, collaborating with various experts to conduct high-quality clinical trials aimed at improving health outcomes across a wide range of medical fields. With a strong emphasis on ethical standards and patient welfare, IRCCS Azienda Ospedaliero-Universitaria di Bologna plays a vital role in shaping the future of medicine through rigorous scientific inquiry and patient-centered care.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Bologna, , Italy
Bologna, , Italy
Patients applied
Trial Officials
Aly Mohamed Alaaeldin Kamaleldin Aly Youssef, MD
Principal Investigator
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported